Abstract:Acquired immune evasion is one of the mechanisms that contributes to the dismal prognosis of cancer. Recently, we observed that different γδ T cell subsets as well as CD8+ αβ T cells infiltrate the pancreatic tissue. Interestingly, the abundance of γδ T cells was reported to have a positive prognostic impact on survival of cancer patients. Since γδ T cells utilize TNF-related apoptosis inducing ligand (TRAIL) for killing of tumor cells in addition to granzyme B and perforin, we investigated the role of the TRAIL-/TRAIL-R system in γδ T cell-cytotoxicity toward pancreatic ductal adenocarcinoma (PDAC) and other cancer cells. Coculture of the different cancer cells with γδ T cells resulted in a moderate lysis of tumor cells. The lysis of PDAC Colo357 cells was independent of TRAIL as it was not inhibited by the addition of neutralizing anti-TRAIL antibodies or TRAIL-R2-Fc fusion protein. In accordance, knockdown (KD) of death receptors TRAIL-R1 or TRAIL-R2 in Colo357 cells had no effect on γδ T cell-mediated cytotoxicity. However, KD of decoy receptor TRAIL-R4, which robustly enhanced TRAIL-induced apoptosis, interestingly, almost completely abolished the γδ T cell-mediated lysis of these tumor cells. This effect was associated with a reduced secretion of granzyme B by γδ T cells and enhanced PGE2 production as a result of increased expression level of synthetase cyclooxygenase (COX)-2 by TRAIL-R4-KD cells. In contrast, knockin of TRAIL-R4 decreased COX-2 expression. Importantly, reduced release of granzyme B by γδ T cells cocultured with TRAIL-R4-KD cells was partially reverted by bispecific antibody [HER2xCD3] and led in consequence to enhanced lysis of tumor cells. Likewise, inhibition of COX-1 and/or COX-2 partially enhanced γδ T cell-mediated lysis of TRAIL-R4-KD cells. The combination of bispecific antibody and COX-inhibitor completely restored the lysis of TRAIL-R4-KD cells by γδ T cells. In conclusion, we uncovered an unexpected novel role of TRAIL-R4 in tumor cells. In contrast to its known pro-tumoral, anti-apoptotic function, TRAIL-R4 augments the anti-tumoral cytotoxic activity of γδ T cells.

Involvement of Cellular Death in Trail/Dr5-Dependent Suppression Induced by Cd4(+)Cd25(+) Regulatory T Cells

Molecular Mechanisms of Resistance to TRAIL-induced Apoptosis in Tumor

Overcoming acquired resistance to TRAIL by chemotherapeutic agents and calpain inhibitor I through distinct mechanisms.

Splenic Stroma-Educated Regulatory Dendritic Cells Induce Apoptosis of Activated CD4 T Cells Via Fas Ligand-Enhanced IFN-γ and Nitric Oxide.

The Involvement Of Tnf-Alpha-Related Apoptosis-Inducing Ligand In The Enhanced Cytotoxicity Of Ifn-Beta-Stimulated Human Dendritic Cells To Tumor Cells

The Involvement of TNF-α-Related Apoptosis-Inducing Ligand in the Enhanced Cytotoxicity of IFN-β-Stimulated Human Dendritic Cells to Tumor Cells

CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation–mediated apoptosis of effector CD4+ T cells

Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways

Association of TRAIL receptor with phosphatase SHP-1 enables repressing T cell receptor signaling and T cell activation through inactivating Lck

Regulatory T Cell–Derived TRAIL Is Not Required for Peripheral Tolerance

Developing TRAIL/TRAIL death receptor-based cancer therapies

CD4+ CD25+ Regulatory T Cells Exhibit Cytotoxicity Against Dendritic Cells

Non‐apoptotic TRAIL function modulates NK cell activity during viral infection

TRAIL-Receptor 4 Modulates γδ T Cell-Cytotoxicity Toward Cancer Cells

Lipopolysaccharide-Induced Expression of Trail Promotes Dendritic Cell Differentiation

Novel Insights into the Synergistic Interaction of a Thioredoxin Reductase Inhibitor and TRAIL: the Activation of the ASK1-ERK-Sp1 Pathway

Regulation of Cancer Metastasis by TRAIL/Death Receptor Signaling

Apoptotic Cell-induced Tolerogenic Dendritic Cells Facilitate Development of CD4+ and CD8+ Regulatory T Cell Subsets

Class Ii Mhc-Independent Suppressive Adhesion of Dendritic Cells by Regulatory T Cells in Vivo

Dose-related immunomodulatory effects of recombinant TRAIL in the tumor immune microenvironment

Single-Cell Transcriptomics Reveals Killing Mechanisms of Antitumor Cytotoxic CD4+ TCR-T Cells